MetLife Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

MetLife Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.97M	Buy	54,326 +4,508	+9%	+$201K	0.01%	1070
2025 Q4	$2.32M	Sell	49,818 -3,596	-7%	-$160K	0.01%	1008
2025 Q3	$2.22M	Hold	53,414	–	–	0.01%	1034
2025 Q2	$1.54M	Hold	53,414	–	–	0.01%	1122
2025 Q1	$1.79M	Buy	53,414 +394	+0.7%	+$14.7K	0.01%	1092
2024 Q4	$2.71M	Buy	53,020 +8,085	+18%	+$452K	0.01%	888
2024 Q3	$2.3M	Hold	44,935	–	–	0.01%	946
2024 Q2	$2.01M	Buy	44,935 +10,916	+32%	+$504K	0.01%	968
2024 Q1	$1.59M	Hold	34,019	–	–	0.01%	1058
2023 Q4	$1.21M	Hold	34,019	–	–	0.01%	1200
2023 Q3	$1.01M	Buy	34,019 +5,972	+21%	+$123K	0.01%	1222
2023 Q2	$505K	Hold	28,047	–	–	﹤0.01%	1685
2023 Q1	$450K	Hold	28,047	–	–	﹤0.01%	1703
2022 Q4	$513K	Buy	28,047 +792	+3%	+$14K	﹤0.01%	1628
2022 Q3	$535K	Buy	27,255 +1,838	+7%	+$37.5K	﹤0.01%	1591
2022 Q2	$474K	Hold	25,417	–	–	﹤0.01%	1703
2022 Q1	$558K	Buy	25,417 +9,063	+55%	+$183K	﹤0.01%	1705
2021 Q4	$465K	Buy	16,354 +4,706	+40%	+$116K	﹤0.01%	1547
2021 Q3	$245K	Hold	11,648	–	–	﹤0.01%	1961
2021 Q2	$220K	Hold	11,648	–	–	﹤0.01%	2105
2021 Q1	$178K	Sell	11,648 -1,084	-9%	-$16.8K	﹤0.01%	2117
2020 Q4	$180K	Hold	12,732	–	–	﹤0.01%	2035
2020 Q3	$200K	Hold	12,732	–	–	﹤0.01%	1866
2020 Q2	$223K	Buy	12,732 +6,897	+118%	+$118K	﹤0.01%	1845
2020 Q1	$85.8K	Hold	5,835	–	–	﹤0.01%	2160
2019 Q4	$146K	Buy	+5,835	New	+$111K	﹤0.01%	2146
2019 Q3	–	Sell	-5,862	Closed	-$147K	–	2340
2019 Q2	$147K	Buy	+5,862	New	+$145K	﹤0.01%	2203

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MetLife Investment Management's CRNX Position: Q1 2026 in Review

MetLife Investment Management increased its Crinetics Pharmaceuticals (CRNX) stake by 9% in Q1 2026, buying an estimated $201K and bringing the position to 54,326 shares worth $1.97M. The position accounts for 0.01% of the portfolio, ranked #1070.

MetLife Investment Management first reported a position in CRNX in Q2 2019 and has held it in 27 quarters since. The position peaked at $2.71M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

MetLife Investment Management held 54,326 shares of Crinetics Pharmaceuticals worth $1.97M as of Q1 2026.
MetLife Investment Management bought 4,508 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $201K.
Crinetics Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1070 holding.
MetLife Investment Management first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 27 quarters since.
MetLife Investment Management's Crinetics Pharmaceuticals position peaked at $2.71M in Q4 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.